SphK2 over-expression promotes osteosarcoma cell growth

Dawei Xu; Hao Zhu; Chengniu Wang; Wei Zhao; Genxiang Liu; Guofeng Bao; Daoran Cui; Jianbo Fan; Fei Wang; Huricha Jin; Zhiming Cui

doi:10.18632/oncotarget.22314

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

SphK2 over-expression promotes osteosarcoma cell growth

Dawei Xu, Hao Zhu, Chengniu Wang, Wei Zhao, Genxiang Liu, Guofeng Bao, Daoran Cui, Jianbo Fan, Fei Wang, Huricha Jin and Zhiming Cui _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:105525-105535. https://doi.org/10.18632/oncotarget.22314

Metrics: PDF 1579 views | HTML 2208 views | ?

Abstract

Dawei Xu1,*, Hao Zhu2,*, Chengniu Wang3, Wei Zhao1, Genxiang Liu2, Guofeng Bao1, Daoran Cui1, Jianbo Fan1, Fei Wang1, Huricha Jin1 and Zhiming Cui1

1Department of Orthopaedics, The Second Affiliated Hospital of Nantong University, Nantong, China

2Department of Orthopaedics, The Fourth Affiliated Hospital of Nantong University, Yancheng, China

3Basic Medical Research Centre, Medical College, Nantong University, Nantong, China

*These authors have contributed equally to this work

Correspondence to:

Zhiming Cui, email: [email protected]

Keywords: osteosarcoma; sphk2; microRNA-19a-3p; oncotarget

Received: May 30, 2017 Accepted: July 13, 2017 Published: November 06, 2017

ABSTRACT

It is needed to explore novel biological markers for early diagnosis and treatment of human osteosarcoma. Sphingosine kinase 2 (SphK2) expression and potential functions in osteosarcoma were studied. We demonstrate that SphK2 is over-expressed in multiple human osteosarcoma tissues and established human osteosarcoma cell lines. Silence of SphK2 by targeted-shRNAs inhibited osteosarcoma cell growth, and induced cell apoptosis. On the other hand, exogenous over-expression of SphK2 could further promote osteosarcoma cell growth. Notably, microRNA-19a-3p (“miR-19a-3p”) targets the 3’ UTR (untranslated region) of SphK2 mRNA. Remarkably, forced-expression of miR-19a-3p silenced SphK2 and inhibited osteosarcoma cell growth. In vivo, SphK2 silence, by targeted-shRNA or miR-19a-3p, inhibited U2OS tumor growth in nude mice. These results suggest that SphK2 could be a novel and key oncotarget protein for OS cell progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22314

Publication Alerts

Post-Publication Promotion

Research Papers:

SphK2 over-expression promotes osteosarcoma cell growth

Abstract